| 1 |
Oettle H,Post S,Neuhaus P,et al.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer:a randomized controlled trial.JAMA,2007,297(3):267-77.
|
| 2 |
Regine WF,Winter KW,Abrams R,et al.A phase III study of adjuvant pre and post chemoradiation(CRT) 5-Fu vs. gemcitabine(G) for resected pancreatic adenocarcinoma.2006,24(suppl 18):A 4007.
|
| 3 |
Neoptolemos JP,Stocken DD,Friess H,et al.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.N Engl J Med,2004,350(12):1200-1210.
|
| 4 |
Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer, 2005. 92(8):1372-81.
|
| 5 |
Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinomaofthepancreas.JClinOncol,1997,15(3):928-937.
|
| 6 |
Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy(chemotherapy plus radiotherapy)to chemotherapy alone.J Natl Cancer Inst,1988,80(10):751-755.
|
| 7 |
Klaassen DJ,MacIntyre JM,Catton GE,et al.Treatment of locally unresectable cancer of the stomach and pancreas:a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol, 1985, 3(3):373-378.
|
| 8 |
Chauffert B,Mornex F,Bonnetain F.Phase III trial comparing initial chemoradiotherapy(intermittent cisplatin and infusional 5-Fu)followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol, 2006, 24(suppl 18):A 4008.
|
| 9 |
Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys,2002,52(5):1293-1302.
|
| 10 |
Li CP,Chao Y,Chi KH,et al.Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer:gemcitabine versus 5-fluorouracil,a randomized controlled study.Int J Radiat Oncol Biol Phys,2003,57(1):98-104.
|
| 11 |
Huguet F,Andre T,Hammel P,et al.Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.J Clin Oncol,2007,25(3):326-331.
|
| 12 |
Burris H, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial.J Clin Oncol,1997,15(6):2403-2413.
|
| 13 |
Sultana A,Smith CT,Cunningham D,et al.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.J Clin Oncol, 2007,25(18):2607-2615.
|
| 14 |
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol,2007,25(15):1960-1966.
|
| 15 |
Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine(G) plus bevacizumab (B)versus gemcitabine plus placebo(P) in patients(pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B(CALGB)80303.J Clin Oncol,2007,25(suppl.18):A 4508.
|
| 16 |
Philip PA,Benedetti J,Fenoglio-Preiser C.Phase III study of gemcitabine(G)plus cetuximab(C)versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma(PC):SWOG S0205 study.2007 ASCO Annual Meeting.
|
| 17 |
Safran H, Iannitti D, Ramanathan R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest,2004,22(5):706-712.
|
| 18 |
Wallace A,Locker GN.Sorafenib(S)plus gemcitabine(G)for advanced pancreatic cancer(PC):a phase II trial of the University of Chicago Phase II Consortium.2007 GI ASCO Annual Meeting.
|
| 19 |
Safran H,Iannitti D,Miner T.GW572016/gemcitabine and GW572016/gemcitabine/oxaliplatin,a two-stage,phase I study for advanced pancreatiobiliary cancer.2006 ASCO Annual Meeting.
|
| 20 |
Cusack JC,Liu R,Xia L,et al.A novel orally active proteasome inhibitor NPI-0052 enhances tumoricidal response to multidrug chemo-and molecular therapy regimens in a panceatic cancer xenograft model.2006 GI ASCO Annual Meeting.
|